
    
      This is a 52-week, open-label, multi-centre study designed to evaluate the safety of
      tralokinumab in a fixed 300 mg dose every 2 weeks, administered subcutaneously in adults and
      adolescents with indequately controlled asthma on medium to high dose inhaled corticosteroid
      plus long acting Î²-2 antagonist. Approximately 26 Japanese subjects will be recruited to
      receive 22 completed.
    
  